Cti Life Sciences Fund

About The Fund

CTI Life Sciences Fund, established in 2006 and based in Montreal, Canada, is a venture capital investment firm that primarily focuses on the life sciences and healthcare sectors. With a deep commitment to the pre-clinical and clinical development stages, they invest in companies located in North America, mainly the United States and Canada, and extend their reach to Europe. The firm prides itself on being a knowledge-driven boutique venture capital firm that catalyzes, transforms, and invests in the future of life sciences. They have a record of over 20 successful investments, 10 exits, and 3 FDA approvals to date. Their mission is to catalyze emerging science, transform business objectives, and invest in scalable companies. They aim to deliver impactful innovations and strong returns to stakeholders across biotechnology and healthcare. CTI positions itself as a catalyst for transformative investments and leverages deep, complementary collective intelligence to deliver strong investment results. The firm's team is comprised of diverse, knowledgeable individuals with extensive experience in business, deep scientific intelligence, and a track record in drug development. They are capable of making rationalized investment decisions with an all-inclusive approach. Key members of the team include Ken Pastor, Laurence Rulleau, Youssef Bennani, and Shermaine Tilley, whose expertise spans investment banking, pharmaceutical R&D, and biotech investing. They combine their business experience with scientific and financial structuring expertise to make informed investments, benefiting shareholders and patients alike. CTI Life Sciences Fund has established themselves in the biotech, medical devices, investment management, and oncology arenas, with a strategy rooted in partnering with companies that show great potential for success and innovation.